Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2003
08/28/2003WO2003070884A2 RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070881A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070823A2 Conjugates comprising a biodegradable polymer and uses therefor
08/28/2003WO2003070805A1 Hydrolytically degradable alkylene oxide based polymers
08/28/2003WO2003070775A1 Novel natural cyclodextrin complexes
08/28/2003WO2003070772A1 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments
08/28/2003WO2003070755A2 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
08/28/2003WO2003070750A2 Rna interference mediated inhibition of hepatitis c virus
08/28/2003WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070743A1 RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070742A1 RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070738A2 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003WO2003070282A2 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
08/28/2003WO2003070281A1 Prostaglandin composition for the treatment of erectile dysfunction
08/28/2003WO2003070280A2 Absorption enhancing agent
08/28/2003WO2003070279A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
08/28/2003WO2003070273A1 A bioadhesive agent
08/28/2003WO2003070272A1 An immunological adjuvant
08/28/2003WO2003070227A1 Taste-masked film-type or wafer-type medicinal preparation
08/28/2003WO2003070226A1 Edible pga coating composition
08/28/2003WO2003070223A1 Sustained release preparations and process for producing the same
08/28/2003WO2003070222A1 Cross-linkable phosphonate-containing supramolecular complexes and their use for delivery of therapeutic and diagnostic agents
08/28/2003WO2003070220A1 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same
08/28/2003WO2003070218A1 Sustained-release ointment for topical administration
08/28/2003WO2003070217A1 Levothyroxine compositions and methods
08/28/2003WO2003070177A2 Use of melatonin analogues for induction of general anesthesia
08/28/2003WO2003070174A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
08/28/2003WO2003070173A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
08/28/2003WO2003070153A2 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
08/28/2003WO2003069998A1 Stable compositions comprising tezacitabine
08/28/2003WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003WO2003057359A3 Microparticles and methods for their production
08/28/2003WO2003053158A3 Malleable protein matrix and uses thereof
08/28/2003WO2003047629A3 Treatment of diseases via the skin
08/28/2003WO2003041690A3 Three-dimensional suspension printing of dosage forms
08/28/2003WO2003041683A3 Orodispersible tablets containing fexofenadine
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003035044A3 Production of starch-gel-based shaped bodies
08/28/2003WO2003035026A3 Polysaccharide-based network and method for the production thereof
08/28/2003WO2003031467A3 Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
08/28/2003WO2003024454A3 Topical composition containing brucine and the use for the treatment of damaged mammalian skin
08/28/2003WO2003022071A3 Colorant for food and pharmaceuticals
08/28/2003WO2003017990A3 Ophthalmic composition comprising an ascomycin
08/28/2003WO2003016522A3 Methods and compounds for the targeting of protein to exosomes
08/28/2003WO2003015656A3 Oral care substance delivery strip
08/28/2003WO2003011239A3 Sunscreen composition
08/28/2003WO2003008932A3 Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy akylene glycols
08/28/2003WO2003000738A3 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate
08/28/2003WO2002058622A3 Sn-38 lipid complexes and methods of use
08/28/2003WO2002043771A3 Conjugates of glycosylated/galactosylated peptide
08/28/2003WO2002041921A3 Compositions for protection against bovine viral diseases
08/28/2003WO2002032914A3 Acylated cellobiose compounds
08/28/2003WO2002015885A3 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
08/28/2003WO2002005800A9 Compositions for sustained release of analgesic agents, and methods of making and using the same
08/28/2003WO2002000839A3 Statement as to federally sponsored research
08/28/2003WO2001085147A3 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF
08/28/2003US20030162953 Chemically-defined non-polymeric valency platform molecules and conjugates thereof
08/28/2003US20030162948 Tumour necrosis factor binding ligands
08/28/2003US20030162841 Biocompatible crosslinked polymers
08/28/2003US20030162835 Method of making particles for use in a pharmaceutical composition
08/28/2003US20030162821 Applying topical mixtures of allantoin, emulsifiers and optionally steroids, nonsteroidal antiinflammatory agents, leukotriene antagonists or monoclonal antibodies, to prevent scarring, ulcers or blisters on skins
08/28/2003US20030162751 Pharmaceutical composition comprising 5' monophosphate ester of riboflavin and solubilized riboflavin
08/28/2003US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen
08/28/2003US20030162739 Antisense molecules and method of controlling expression of gene function by using the same
08/28/2003US20030162726 Sugar-free products with improved characteristics
08/28/2003US20030162721 Anticancer agents; bioavailability; sustained release
08/28/2003US20030162719 Immobilization of active materials
08/28/2003US20030162711 Pharmaceutical formulation
08/28/2003US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains
08/28/2003US20030162693 Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
08/28/2003US20030161957 Impregnating polymer with active ingredient solution, adding compressed fluid until precipitation of active ingredient caused by compressed fluid antisolvent effect, removing the solvent and compressed fluid; drug delivery
08/28/2003US20030161895 Comprising water, Xanthan gum, Magnesium aluminum silicate, Kaolin, Silicon dioxide, Sodium sulfacetamide, Sodium thiosulfate, Glyceryl stearate, PEG-100 Stearate, Quillaia saponaria extract, Benzyl alcohol, sulfur, high sorption base
08/28/2003US20030161888 Pharmaceutical Composition
08/28/2003US20030161885 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161883 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
08/28/2003US20030161873 Method for stabilizing preparation
08/28/2003US20030161871 Intensifying water solubility of vitamin B12 using solubilizers such as complexing agents, liposomes, oils, surfactants, cosolvents or (micro)emulsions; multicompartment drug delivery kits
08/28/2003US20030161870 Dual enhancer composition for topical and transdermal drug delivery
08/28/2003US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition
08/28/2003US20030161858 Mixtures of cement powders, vitamins, hormones, antibiotics, antitumor agents, somatotropins, calcium phosphates or proteins dissolved, dispersed or emulsified in oils; bone disorders
08/28/2003US20030161846 Oral administration of an emulsion pre-concentrate of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat; forms an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability
08/28/2003US20030161837 Crosslinking an immunoglobulin or fragment thereof with anN-hydroxyl-succinimide ester and a maleimide linked vis a polyethyleneoxide spacer and incubating with a polypeptide having a sulfhydryl group (an allergen or autoantigen)
08/28/2003US20030161809 Complexes; drug delivery
08/28/2003US20030161791 Water-soluble polymer conjugates of retinoic acid
08/28/2003US20030159953 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
08/28/2003DE29924428U1 New topical composition for treating herpes family viruses, reduces treatment-related erythema but maintains high activity
08/28/2003CA2477321A1 Absorption enhancing agent
08/28/2003CA2477191A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003CA2477068A1 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
08/28/2003CA2476958A1 An immunological adjuvant
08/28/2003CA2476834A1 Natural cyclodextrin complexes of cannabinoids
08/28/2003CA2476626A1 Microparticles with adsorbed polypeptide-containing molecules
08/28/2003CA2476452A1 Electroporation methods for introducing bioactive agents into cells
08/28/2003CA2476423A1 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
08/28/2003CA2476422A1 Topiramate salts and compositions comprising and methods of making and using the same
08/28/2003CA2476402A1 Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
08/28/2003CA2476380A1 Stable compositions comprising tezacitabine
08/28/2003CA2476112A1 Rna interference mediated inhibition of interleukin gene expression using short interfering nucleic acid (sina)
08/28/2003CA2475923A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient